



Supplementary Figure 2. Comparison of OS according to the type of drug prescribed in the TKI group. OS was compared between TARE versus sorafenib (A, B), TARE versus lenvatinib (C, D), and sorafenib versus lenvatinib (E, F) before and after applying IPTW. IPTW, inverse probability of treatment weighting; OS, overall survival; TARE, transarterial radioembolization; TKI, tyrosine kinase inhibitor.